Cresco Labs (CRLBF) Income from Non-Controlling Interests (2020 - 2026)
Cresco Labs (CRLBF) reported Income from Non-Controlling Interests of -$3.9 million for Q1 2026, down 391.52% on a YoY basis from $1.4 million in Q1 2025, and down 189.64% quarter-over-quarter from -$1.4 million in Q4 2025.
Cresco Labs (CRLBF) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
Cresco Labs has reported Income from Non-Controlling Interests for 7 years, with the latest figure at -$3.9 million in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 391.52% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at -$7.8 million (down 177.69% YoY), and the FY2025 full-year result was -$4.6 million, down 133.24% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$3.9 million, down from -$1.4 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $6.5 million in Q3 2022, with the low at -$19.3 million in Q4 2022.
- Historically, Income from Non-Controlling Interests has averaged -$162058.8 across 5 years, with a median of $2.2 million in 2023.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests slumped 783.66% — and 2024, when it surged 278.19%.
- Cresco Labs' Income from Non-Controlling Interests stood at -$19.3 million in 2022, then soared by 111.58% to $2.2 million in 2023, then surged by 115.45% to $4.8 million in 2024, then tumbled by 128.29% to -$1.4 million in 2025, then sank by 189.64% to -$3.9 million in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$3.9 million (Q1 2026), -$1.4 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | Cresco Labs | - | - | 75.45 Mn | -3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.94 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Sep 30, 2025 | -4.91 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | -802,000.00 |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 2.85 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | -6.93 Mn |
| Mar 31, 2023 | -1.76 Mn |
| Dec 31, 2022 | -19.29 Mn |
| Sep 30, 2022 | 6.54 Mn |
| Jun 30, 2022 | 5.25 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 7.19 Mn |
| Jun 30, 2021 | 7.48 Mn |